B Coudert
Overview
Explore the profile of B Coudert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
1361
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Molinier O, Besse B, Barlesi F, Audigier-Valette C, Friard S, Monnet I, et al.
ESMO Open
. 2021 Dec;
7(1):100353.
PMID: 34953398
Background: Immunotherapy using inhibitors targeting immune checkpoint programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) is currently the standard of care in patients with advanced non-small-cell lung cancer (NSCLC)....
2.
Dano D, Lardy-Cleaud A, Monneur A, Quenel-Tueux N, Levy C, Mouret-Reynier M, et al.
ESMO Open
. 2021 Jul;
6(4):100220.
PMID: 34303929
Background: Primary inflammatory breast cancer (IBC) is a rare and aggressive entity whose prognosis has been improved by multimodal therapy. However, 5-year overall survival (OS) remains poor. Given its low...
3.
Petitcollin A, Azzopardi N, Pierga J, Ternant D, Navarro-Teulon I, Desvignes C, et al.
Eur J Clin Pharmacol
. 2021 Jul;
77(12):1861-1873.
PMID: 34245336
Aims: To describe the sources of interindividual variability of bevacizumab and trastuzumab pharmacokinetics in early-stage breast cancer, and to study the relationship between exposure and both early clinical response and...
4.
Kaderbhai C, Coudert B, Bertaut A, Adnet J, Favier L, Lagrange A, et al.
Cancer Radiother
. 2020 May;
24(4):279-287.
PMID: 32439358
Purpose: The present study evaluated the outcomes of concurrent weekly docetaxel and platinum-based drug doublet in association with concurrent thoracic radiotherapy (TR) in the curative treatment of stage III locally...
5.
Fontaine-Delaruelle C, Mazieres J, Cadranel J, Mastroianni B, Dubos-Arvis C, Dumont P, et al.
Respir Med Res
. 2020 May;
77:58-66.
PMID: 32416585
Background: Lung cancer in women is on the rise, with a higher proportion occurring in lifelong never-smokers. Lung cancer in never-smokers (LCINS) exhibits a high frequency of driver oncogene alterations....
6.
Vincent L, Jankowski C, Arnould L, Coudert B, Rouzier R, Reyal F, et al.
Gynecol Obstet Fertil Senol
. 2020 Mar;
48(9):679-686.
PMID: 32205278
Objectives: The aim of this study was to compare the value of F-fluorodesoxyglucose positron emission tomography (F-FDG PET/CT) with CGFL/Curie nomogram to predict a pathologic complete response (pCR) after neoadjuvant...
7.
Vokes E, Ready N, Felip E, Horn L, Burgio M, Antonia S, et al.
Ann Oncol
. 2018 Feb;
29(4):959-965.
PMID: 29408986
Background: Long-term data with immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) are limited. Two phase III trials demonstrated improved overall survival (OS) and a favorable safety profile with the...
8.
Jankowski C, Guiu S, Cortet M, Charon-Barra C, Desmoulins I, Lorgis V, et al.
Breast Cancer Res Treat
. 2016 Nov;
161(1):73-81.
PMID: 27807808
Purpose: The aim of this study was to assess the Institut Gustave Roussy/M.D. Anderson Cancer Center (IGR/MDACC) nomogram in predicting pathologic complete response (pCR) to preoperative chemotherapy in a cohort...
9.
Beltjens F, Bertaut A, Pigeonnat S, Loustalot C, Desmoulins I, Charon-Barra C, et al.
Eur J Cancer Care (Engl)
. 2015 Oct;
26(2).
PMID: 26503126
HER2 status is essential for breast cancer subtyping and for systemic treatment decisions as patients with HER2-positive tumours can benefit from anti-HER2 targeted therapies. However, few data are available on...
10.
Guiu S, Reynier M, Toure M, Coudert B
J Oncol
. 2013 Jun;
2013:854121.
PMID: 23737784
Since 2005, major progresses have been made in the neoadjuvant treatment of HER2-positive breast cancer. Trastuzumab introduction associated with chemotherapy has been the first major step leading to the improvement...